Graphite Bio divests gene editing pipeline to newly-formed Kamau Therapeutics after announcing reverse merger with Lenz Therapeutics

Kamau Therapeutics has emerged from stealth mode after inking a deal with Graphite Bio for its genome editing assets. Kamau’s debut comes less than a month after Graphite entered a reverse merger deal with Lenz Therapeutics to form a new combined company.

San Francisco-based Kamau was co-founded by Stanford scientists…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks